Darong Yang

Dr. Darong Yang

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2013 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CXCheng Xu
Cheng Xu
DYDarong Yang
Darong Yang
LMLin Mei
Lin Mei
QLQiuhong Li
Qiuhong Li
HZHaizhen Zhu
Haizhen Zhu
TWTaihong Wang
Taihong Wang

11 March 2013 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
CXCheng Xu
Cheng Xu
DYDarong Yang
Darong Yang
LMLin Mei
Lin Mei
BLBingan Lu
Bingan Lu
LCLibao Chen
Libao Chen
TWTaihong Wang
Taihong Wang

10 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
DYDarong Yang
Darong Yang
CZChaohui Zuo
Chaohui Zuo
XWXiaohong Wang
Xiaohong Wang
XMXianghe Meng
Xianghe Meng
BXBinbin Xue
Binbin Xue
HZHaizhen Zhu
Haizhen Zhu
The absence of a robust cell culture system for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection has limited the analysis of the virus lifecycle and drug discovery. We have established a hepatoma cell line, HLCZ01, the first cell line, to the authors’ knowledge, supporting the entire lifecycle of both HBV and HCV. HBV surface antigen (HBsAg)-positive particles can be observed in the supernatant and the lumen of the endoplasmic reticulum of the cells via electron microscopy. Interestingly, HBV and HCV clinical isolates propagate in HLCZ01 cells. Both viruses replicate in the cells without evidence of overt interference. HBV and HCV entry are blocked by antibodies against HBsAg and human CD81, respectively, and the replication of HBV and HCV is inhibited by antivirals. HLCZ01 cells mount an innate immune response to virus infection. The cell line provides a powerful tool for exploring the mechanisms of virus entry and replication and the interaction between host and virus, facilitating the development of novel antiviral agents and vaccines. Significance More than 500 million people are persistently infected with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) and are at a risk of developing chronic hepatitis, cirrhosis, and liver cancer. The absence of robust cell culture systems for both viral infections limits the understanding of the virus lifecycle and pathogenesis required for the development of vaccine and antivirals. We have established a novel human hepatoma cell line termed “HLCZ01” that supports the entire lifecycle of both HBV and HCV produced both in cell culture and clinically. This cell line provides a powerful tool for addressing the virus lifecycle and the development of antivirals and vaccines.

1 December 2017 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
YQYuwen Qin
Yuwen Qin
BXBinbin Xue
Binbin Xue
CLChunyan Liu
Chunyan Liu
XWXiaohong Wang
Xiaohong Wang
RTRenyun Tian
Renyun Tian
HZHaizhen Zhu
Haizhen Zhu
Activation of innate immunity is essential for host cells to restrict the spread of invading viruses and other pathogens. However, attenuation or termination of signaling is also necessary for preventing immune-mediated tissue damage and spontaneous autoimmunity. Here, we identify nucleotide binding oligomerization domain (NOD)-like receptor X1 (NLRX1) as a negative regulator of the mitochondrial antiviral signaling protein (MAVS)-mediated signaling pathway during hepatitis C virus (HCV) infection. The depletion of NLRX1 enhances the HCV-triggered activation of interferon (IFN) signaling and causes the suppression of HCV propagation in hepatocytes. NLRX1, a HCV-inducible protein, interacts with MAVS and mediates the K48-linked polyubiquitination and subsequent degradation of MAVS via the proteasomal pathway. Moreover, poly(rC) binding protein 2 (PCBP2) interacts with NLRX1 to participate in the NLRX1-induced degradation of MAVS and the inhibition of antiviral responses during HCV infection. Mutagenic analyses further revealed that the NOD of NLRX1 is essential for NLRX1 to interact with PCBP2 and subsequently induce MAVS degradation. Our study unlocks a key mechanism of the fine-tuning of innate immunity by which NLRX1 restrains the retinoic acid-inducible gene I-like receptor (RLR)-MAVS signaling cascade by recruiting PCBP2 to MAVS for inducing MAVS degradation through the proteasomal pathway. NLRX1, a negative regulator of innate immunity, is a pivotal host factor for HCV to establish persistent infection. IMPORTANCE Innate immunity needs to be tightly regulated to maximize the antiviral response and minimize immune-mediated pathology, but the underlying mechanisms are poorly understood. In this study, we report that NLRX1 is a proviral host factor for HCV infection and functions as a negative regulator of the HCV-triggered innate immune response. NLRX1 recruits PCBP2 to MAVS and induces the K48-linked polyubiquitination and degradation of MAVS, leading to the negative regulation of the IFN signaling pathway and promoting HCV infection. Overall, this study provides intriguing insights into how innate immunity is regulated during viral infection.

6 June 2014 in Oncotarget
Verified
Journal Article
Open access
PDF file
NLNianli Liu
Nianli Liu
CZChaohui Zuo
Chaohui Zuo
XWXiaohong Wang
Xiaohong Wang
TCTianran Chen
Tianran Chen
DYDarong Yang
Darong Yang
HZHaizhen Zhu
Haizhen Zhu
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an attractive death ligand in targeted cancer therapy. Many cancer cells are refractory to TRAIL-induced cell death and the mechanisms underlying resistance are unclear. The molecular mechanisms of HCC and gastric cancer cells resistant to TRAIL-induced apoptosis were explored using molecular biological and immunological methods. In vivo experiments were conducted to study the effect of interferon stimulated gene 12a (ISG12a) on human liver cancer xenografts in mice. ISG12a decreases in TRAIL-resistant cancer cells. ISG12a regulates the sensitivity of cancer cells to TRAIL in vitro and in vivo. MicroRNA-942 (miR-942) is inversely correlated with ISG12a expression in cancer cells and tissues. Forced expression of miR-942 in TRAIL-sensitive cells significantly reduces endogenous ISG12a level and changes the TRAIL sensitive phenotype to a resistant one. Knockdown of miR-942 expression in TRAIL-resistant cells restores the expression of ISG12a and sensitizes the cells to TRAIL treatment. AKT control TRAIL resistance of cancer cells through downregulation of ISG12a by miR-942. Downregulation of ISG12a by miR-942 is needed to maintain the TRAIL-resistant phenotype of cancer cells and favors cancer cell survival. MiR-942 may offer a novel drug response marker with important implications in designing new therapeutics for TRAIL resistant tumors.

1 April 2018 in Pancreatology
Verified
Journal Article
Closed access
CZChaohui Zuo
Chaohui Zuo
YHYuan Hong
Yuan Hong
XQXiaoxin Qiu
Xiaoxin Qiu
DYDarong Yang
Darong Yang
NLNianli Liu
Nianli Liu
ZLZhuo Liu
Zhuo Liu